Drug Profile
Copper histidine subcutaneous - Cyprium Therapeutics
Alternative Names: Copper histidinate; CUTX 101Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator National Institute of Child Health and Human Development
- Developer Cyprium Therapeutics; National Institute of Child Health and Human Development
- Class Heavy metals; Imidazoles; Small molecules
- Mechanism of Action Heavy metal replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Menkes kinky hair syndrome
Most Recent Events
- 05 Mar 2024 Interim pharmacodynamics data from a preclinical studies in Menkes kirky hair syndrome released by Cyprium Therapeutics
- 06 Dec 2023 Cyprium Therapeutics completes asset transfer of copper histidinate subcutaneous for Menkes kinky hair syndrome to Sentynl Therapeutics
- 06 Dec 2023 Sentynl Therapeutics plans to complete the rolling NDA submission for Menkes kinky hair syndrome to US FDA, in 2024